# A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

> **NCT06442436** · PHASE1 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (estimated)

## Conditions studied

- Hepatic Impairment (HI)

## Interventions

- **DRUG:** Nemtabrutinib

## Key facts

- **NCT ID:** NCT06442436
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-24
- **Primary completion:** 2026-09-14
- **Final completion:** 2026-09-14
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06442436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06442436, "A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06442436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*